OKYO Pharma Limited

1.50
0.16 (11.94%)
At close: Apr 23, 2025, 3:59 PM
1.50
0.00%
After-hours: Apr 23, 2025, 04:05 PM EDT
11.94%
Bid 1.38
Market Cap 50.83M
Revenue (ttm) n/a
Net Income (ttm) -7.09K
EPS (ttm) -0.38
PE Ratio (ttm) -3.95
Forward PE -8.92
Analyst Buy
Ask 1.61
Volume 228,676
Avg. Volume (20D) 171,459
Open 1.45
Previous Close 1.34
Day's Range 1.40 - 1.70
52-Week Range 0.81 - 1.74
Beta -4.15

About OKYO

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incor...

Industry Biotechnology
Sector Healthcare
IPO Date May 17, 2022
Employees 3
Stock Exchange NASDAQ
Ticker Symbol OKYO
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for OKYO stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 366.67% from the latest price.

Stock Forecasts
2 months ago
+2.88%
OKYO Pharma shares are trading higher after the co... Unlock content with Pro Subscription
3 months ago
+0%
OKYO Pharma shares are trading higher after the company announced it received $1.4 million in non-dilute funding.